Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy
- PMID: 29950907
- PMCID: PMC6018893
- DOI: 10.2147/JEP.S162059
Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy
Abstract
Cisplatin is a widely used antineoplastic agent in the treatment of various cancers. Peripheral neuropathy is a well-known side effect of cisplatin and has the potential to result in limiting and/or reducing the dose, decreasing the quality of life. Unfortunately, the mechanism for cisplatin-induced neuropathy has not been completely elucidated. Currently, available treatments for neuropathic pain (NP) are mostly symptomatic, insufficient and are often linked with several detrimental side effects; thus, effective treatments are needed. Cannabinoids and agmatine are endogenous modulators that are implicated in painful states. This review explains the cisplatin-induced neuropathy and antinociceptive effects of cannabinoids and agmatine in animal models of NP and their putative therapeutic potential in cisplatin-induced neuropathy.
Keywords: agmatine; anandamide; cisplatin; neuropathy.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
References
-
- Tsang RY, Al-Fayea T, Au HJ. Cisplatin overdose: toxicities and management. Drug Safety. 2009;32(12):1109–1122. - PubMed
-
- Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science. 1995;270(5243):1842–1845. - PubMed
-
- Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9–17. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
